Pathkey.ai Limited · ASX:PKY
Pathkey.ai — Shareholder Meeting (November 2021)
15 slides from Pathkey.ai's shareholder meeting presentation, Nov 18, 2021
Slide 1: Annual General Meeting 2021
Annual General Meeting 2021 Company (ASX:OPL)Introduction www.opyl.ai ASX:OPL September 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Opyl Limited (“Opyl”). Each recipient of this presentation is deemed to have agreed to accept the qualifications, limitations and disclaimers set out below. None of Opyl, its subsidiaries or respective directors, officers, employees, advisers or repr
Slide 3: What does Opyl do
What does Opyl do Opyl is a healthcare data optimisation company Opyl’s purpose is to match eligible, motivated patients to clinical trials anywhere in the world, solving one of the most significant problems in clinical research Opyl leverages big data and applies AI to design smarter clinical trial
Slide 4: What’s the problem Opyl’s trying to solve
What’s the problem Opyl’s trying to solve Patient recruitment to clinical trials is a key determinant of trial success 1 86% of clinical trials fail to reach recruitment targets , 2 costing hundreds of millions of dollars in trial budget blow outs each year 3 The one who pays the real price, is the
Slide 5: Company snapshot
Company snapshot Digital health company delivering AI-enabled clinical trial efficiency solutions 3 platforms in development – 2 on market (MVP) generating early stage revenue Customers: global biopharma, medtech, govt & CRO/sites (US and APAC) Based in Melbourne, Australia with 7.8 FTE $1.55m Nov 2
Slide 6: Social Insights
Social Insights Clinical trial Social Insights and real-world Protocol design and recruitment data analysis clinical trial prediction MVP on market - May 2021 MVP on market – Feb 2021 POC stage – 3 successful data trials Collecting patient data - on target Revenue driver - $700k.p.a (consulting) Dis
Slide 7: Opin: Business model
Opin: Business model Data capture device with multiple revenue opportunities 1 3 Feature Feature page trials DataData mining mining Customers pay for a trial feature page, Customers pay to search the Opin database bespoke social media strategy and for matched, eligible patients precision advertising
Slide 8: Opin is a two way data optimisation multi-platform
Opin is a two way data optimisation multi-platform Multiple value capture and value creation features Opyl’s data platform and market offering is global, scalable and compliant People Clinical trial recruitment Protocol design (co-design) Trial feasibility studies Clinical research investment evalua
Slide 9: Making Opin work
Making Opin work • Clear development roadmap – Digital Health CRC • In-house team of developers – now • Clarity on IP position and IP strategy – FB Rice • Large marketing investment to grow market share and data • User experience focus – add value • Aim to be HIPPA certified, and ISO accredited – tr
Slide 10: How we are different from competitors
How we are different from competitors • Patient first approach – add value to drive data • Social media marketing and SEO/growth expertise in-house • Leaders in digital precision interruption and permission digital marketing • Social Insights/ listening capabilities and platform to accelerate digita
Slide 11: Trial Key use cases
@ trialkey use cases » Model a proposed trial protocol and adjust variables to improve PoS reducing risk of failure Biopharma, Medtech, medical research institutes » Augment early drug/device procurement decisions - identifying candidates most likely to reach market Government, health insurance b> I
Slide 12: Trial Key development timeline
Trial Key development timeline TT —— Nov Dec Jan Feb Mar Apr May Jun Jul. Aug Sep Oct Noy Dec Jan Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2019 2019 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 2021 @ Model build © Dat
Slide 13: Looking forward
Looking forward • Building validation Onboarding new recruitment customers each month Successfully recruited one of first trial – exceeded target Social Insights • Achieving scale Contracts averages exceeding $100k+ Building sales and partnering capacity • Going global New languages in Q3 – going gl
Slide 14: Leadership
Leadership A leadership team experienced in AI, digital transformation, clinical trials and scale strategy Chief Executive Officer Chairman Non-Executive Director Executive Director / CTO Michelle is an award-winning recognised Julian brings global expertise in leading Megan is Group Research Office
Slide 15: Opyl
Opy!